James Mangan, MD, provides a general overview of the myelodysplastic syndromes (MDS), their epidemiology, pathophysiology and prognosis, and examines a series of prominent MDS trials from ASH 2016 performed in patients with low or intermediate risk MDS. These trials involved the immunomodulator lenalidomide with or without erythropoietin; a comparison of the methylating agents decitabine and azacitadine; luspatercept for transfusion burden; and enasidenib in patients with IDH2-positive MDS.
Related Links:
Published
March 14, 2017
Created by
BROADCASTMED